Organon & Co. (OGN) Competitors $14.52 -0.05 (-0.31%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$14.57 +0.05 (+0.38%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OGN vs. SMMT, ITCI, MRNA, GMAB, RDY, VTRS, ASND, PCVX, QGEN, and ROIVShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Summit Therapeutics Intra-Cellular Therapies Moderna Genmab A/S Dr. Reddy's Laboratories Viatris Ascendis Pharma A/S Vaxcyte Qiagen Roivant Sciences Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of OGN or SMMT? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, OGN or SMMT? Organon & Co. has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500. Does the MarketBeat Community favor OGN or SMMT? Summit Therapeutics received 290 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 58.56% of users gave Summit Therapeutics an outperform vote while only 33.96% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1833.96% Underperform Votes3566.04% Summit TherapeuticsOutperform Votes30858.56% Underperform Votes21841.44% Does the media prefer OGN or SMMT? In the previous week, Summit Therapeutics had 5 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for Summit Therapeutics and 11 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.40 beat Summit Therapeutics' score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate OGN or SMMT? Organon & Co. currently has a consensus target price of $20.80, suggesting a potential upside of 43.30%. Summit Therapeutics has a consensus target price of $35.44, suggesting a potential upside of 74.43%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, OGN or SMMT? Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.58$864M$3.334.36Summit Therapeutics$700K21,413.80-$614.93M-$0.31-65.55 Is OGN or SMMT more profitable? Organon & Co. has a net margin of 13.49% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Summit Therapeutics N/A -85.42%-52.66% SummaryOrganon & Co. beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.74B$6.90B$5.63B$19.40BDividend Yield7.28%2.75%5.33%3.75%P/E Ratio4.367.2623.5333.04Price / Sales0.58218.61388.1926.59Price / Cash3.1265.6738.1717.55Price / Book-53.766.386.894.53Net Income$864M$142.34M$3.20B$1.02B7 Day Performance-5.32%-5.15%-3.06%-1.30%1 Month Performance-2.62%-7.55%1.51%-4.04%1 Year Performance-22.79%-11.06%9.35%2.59% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.7547 of 5 stars$14.52-0.3%$20.80+43.3%-22.8%$3.74B$6.40B4.3610,000News CoveragePositive NewsSMMTSummit Therapeutics2.8186 of 5 stars$20.69+4.8%$34.11+64.9%+390.8%$15.26B$700,000.00-73.89110Analyst UpgradeNews CoverageITCIIntra-Cellular Therapies3.584 of 5 stars$131.70+0.0%$106.08-19.5%+90.5%$14.00B$680.50M-151.38560Analyst ForecastNews CoveragePositive NewsMRNAModerna4.0977 of 5 stars$34.17+4.6%$59.00+72.7%-70.8%$13.18B$3.20B-3.683,900GMABGenmab A/S3.9 of 5 stars$19.29-2.4%$41.33+114.3%-33.5%$12.77B$21.53B11.092,204Short Interest ↑News CoverageGap DownRDYDr. Reddy's Laboratories3.3939 of 5 stars$13.72+0.0%$17.00+24.0%-10.1%$11.45B$311.31B21.8424,800Positive NewsHigh Trading VolumeVTRSViatris1.8703 of 5 stars$9.30+1.6%$10.50+12.9%-27.3%$11.10B$14.74B-12.5737,000Short Interest ↑ASNDAscendis Pharma A/S3.1232 of 5 stars$167.99+1.2%$204.64+21.8%+2.3%$10.20B$363.64M-23.661,017News CoveragePositive NewsPCVXVaxcyte2.0634 of 5 stars$73.82-1.1%$147.50+99.8%+1.7%$9.51BN/A-16.05160News CoveragePositive NewsQGENQiagen3.4085 of 5 stars$39.87+0.5%$47.71+19.7%-4.6%$8.85B$1.98B111.026,030Short Interest ↑News CoverageROIVRoivant Sciences2.3706 of 5 stars$10.83+0.4%$18.08+67.0%-1.5%$7.73B$122.59M-72.20860Positive News Remove Ads Related Companies and Tools Related Companies SMMT Alternatives ITCI Alternatives MRNA Alternatives GMAB Alternatives RDY Alternatives VTRS Alternatives ASND Alternatives PCVX Alternatives QGEN Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGN) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGN Stock Free OGN Stock Alerts